Loading...

APC anti-mouse CD49b (pan-NK cells) Antibody

Pricing & Availability
Clone
DX5 (See other available formats)
Regulatory Status
RUO
Other Names
α2 integrin, VLA-2 α chain, DX5, Integrin α2 chain, ITGA2
Isotype
Rat IgM, κ
Ave. Rating
Submit a Review
Product Citations
publications
DX5_APC_100507
C57BL/6 mouse splenocytes stained with NK1.1 PE and DX5 APC
  • DX5_APC_100507
    C57BL/6 mouse splenocytes stained with NK1.1 PE and DX5 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
108909 25 µg 67€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108910 100 µg 214€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

DX5 antigen has been recently characterized as CD49b. It is a 150 kD integrin α chain also known as α2 integrin, VLA-2 α chain, and integrin α2 chain. CD49b non-covalently associates with CD29 (β1 integrin) to form the CD49b/CD29 complex known as VLA-2, a receptor for collagen and laminin. CD49b is expressed on platelets, the majority of NK cells, NKT cells, and a small subset of CD8+ T cells (this population can be significantly increased following viral infection). DX5 is used for the identification and isolation of NK cells, and is especially useful for identifying NK cells in mice lacking the NK1.1 antigen.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-propagated NK1.1+ cells from C57BL/6 mice
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified with APC under optimal conditions, and is at >85% purity.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

The DX5 clone detects cells expressing relatively high levels of CD49b and may not be useful for the detection of cells expressing low levels of CD49b. DX5 does not block NK cell killing or binding to collagen in vitro. Additional reported applications (for the relevant formats) include: complement-mediated cytotoxicity2 and immunohistochemical staining5 of formalin-fixed and paraffin-embedded tissue sections as well as immunohistochemical staining of acetone-fixed frozen sections10. The binding of DX5 antibody to splenic NK cells can be blocked by HMa2 antibody.

Application References

(PubMed link indicates BioLegend citation)
  1. Arase H, et al. 2001. J. Immunol. 167:1141. (FC)
  2. Sepulveda H, et al. 1999. J. Immunol. 163:1133.
  3. Norian LA and Allen PM. 2004. J. Immunol. 173:835. (FC)
  4. Andoniou CE, et al. 2005. Nature Immunology 6:1011.
  5. Oertelt S, et al. 2006. J. Immunol. 177:1655. (IHC) PubMed
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370.
  7. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  8. Qui Q, et al. 2010. J. Immunol. 184:1681. (FC) PubMed
  9. Busche A, et al. 2011. J. Immunol. 186:2918. PubMed
  10. Kim HR, et al. 2011. Nephrology 16:545. (IHC) PubMed
  11. Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed
  12. Younos IH, et al. 2012. Int Immunopharmacol. 13:245. PubMed
  13. Honjo K, et al. 2012. PNAS. PubMed.
  14. Huang HN, et al. 2013. Biomaterials. 34:10151. PubMed
Product Citations
  1. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  2. del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed
  3. Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed
  4. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  5. Rabia E, et al. 2023. Front Immunol. 14:1168444. PubMed
  6. Ludwik KA, et al. 2020. Cell Reports. 32(3):107931. PubMed
  7. Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed
  8. Page N, et al. 2018. Immunity. 48:937. PubMed
  9. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  10. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  11. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  12. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
  13. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  14. Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed
  15. Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
  16. Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed
  17. Ho V, et al. 2016. PLoS One. 11:e0168072. PubMed
  18. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  19. Ludwik KA, et al. 2021. STAR Protocols. 2(1):100270. PubMed
  20. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  21. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  22. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  23. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  24. Rohner L, et al. 2020. Sci Rep. 0.570833333. PubMed
  25. Cohen M, et al. 2010. J Immunol. 185:5869. PubMed
  26. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  27. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  28. Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed
  29. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
  30. Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed
  31. Gentek R, et al. 2018. Immunity. 48:1160. PubMed
  32. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
  33. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  34. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  35. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  36. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  37. Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed
  38. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
  39. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  40. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  41. Jovicic N, et al. 2015. PLoS One. 10: 0134089. PubMed
  42. Braza MS et al. 2018. Immunity. 49(5):819-828 . PubMed
  43. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  44. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  45. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed
  46. Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed
  47. Honjo K, et al. 2012. Proc Natl Acad Sci U S A. 109:15882. PubMed
  48. Younos I, et al. 2012. Int Immunopharmacol. 13:245. PubMed
  49. Pinto AR, et al. 2012. PLoS One. 7:e36814. PubMed
RRID
AB_313416 (BioLegend Cat. No. 108909)
AB_313416 (BioLegend Cat. No. 108910)

Antigen Details

Structure
Integrin α chain, 150 kD
Distribution

NK cells, subset of T cells

Function
Adhesion
Ligand/Receptor
Collagen, laminin
Cell Type
NK cells, T cells
Biology Area
Cell Adhesion, Cell Biology, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Arase H, et al. 2001. J. Immunol. 167:1141.
2. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
3. Sasaki K, et al. 2003. Int. Immunol. 15:701.
4. Inoue O, et al. 2003. J. Cell Biol. 160:769.

Gene ID
16398 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD49b
Specificity Alt (DOES NOT SHOW ON TDS):
CD49b
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD49b on UniProt.org
Go To Top Version: 1    Revision Date: 11.30.2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account